CTA
DRNA

Carillon Tower Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Carillon Tower Advisers’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$24.7M Sell
1,120,359
-56,154
-5% -$1.24M 0.15% 203
2020
Q3 		$21.2M Buy
1,176,513
+56,154
+5% +$1.16M 0.28% 126
2020
Q2 		$28.5M Hold
1,120,359
– – 0.22% 146
2020
Q1 		$19.4M Hold
1,120,359
– – 0.19% 175
2019
Q4 		$24.7M Hold
1,120,359
– – 0.16% 218
2019
Q3 		$16.1M Buy
+1,120,359
New +$16M 0.11% 280

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return